High background in ELISpot assays is associated with elevated levels of immune activation in HIV-1-seronegative individuals in Nairobi-Reference-Cited by-同舟云学术

High background in ELISpot assays is associated with elevated levels of immune activation in HIV-1-seronegative individuals in Nairobi

Published:2018-07-04 Issue:3 Volume:6 Page:392-401
ISSN:2050-4527
Container-title:Immunity, Inflammation and Disease
language:en
Short-container-title:

Author:

Liu Amy Y.¹,De Rosa Stephen C.²³,Guthrie Brandon L.¹,Choi Robert Y.⁴,Kerubo-Bosire Rose⁵,Richardson Barbra A.³⁶⁷,Kiarie James⁸,Farquhar Carey¹⁴⁶,Lohman-Payne Barbara⁴⁶⁹^ORCID

Affiliation:

1. Department of Epidemiology; University of Washington; Seattle Washington USA

2. Department of Laboratory Medicine; University of Washington; Seattle Washington USA

3. Vaccine and Infectious Disease Division; Fred Hutchinson Cancer Research Center; Seattle Washington USA

4. Department of Medicine; University of Washington; Seattle Washington USA

5. Centre for Public Health Research; Kenya Medical Research Institute; Nairobi Kenya

6. Department of Global Health; University of Washington; Seattle Washington USA

7. Department of Biostatistics; University of Washington; Seattle Washington USA

8. Department of Obstetrics and Gynaecology; Kenyatta National Hospital; Nairobi Kenya

9. Department of Paediatrics and Child Health; University of Nairobi; Nairobi Kenya

Funder

National Institute of General Medical Sciences

Fogarty International Center

National Institutes of Health

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/iid3.231/fullpdf

Reference26 articles.

1. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood;Schmittel;J. Immunol. Methods,1997

2. Application of the IFN-g ELISPOT assay to quantify T cell responses against proteins;Schmittel;J. Immunol. Methods,2001

3. The role of IFN-gamma Elispot assay in HIV vaccine research;Streeck;Nat. Protoc,2009

4. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials;Cox;AIDS Res. Hum. Retroviruses,2005

5. 2013 http://www.oxfordimmunotec.com/international/wp-content/uploads/sites/3/Final-File-PI-TB-US-V6.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization and validation of flow cytometry method for quantification of SARS-CoV-2 antigen-reactive human memory T cells;Russian Journal of Infection and Immunity;2023-10-24

2. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV;Microbiology Spectrum;2023-06-15

3. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study;PLOS Medicine;2022-10-27

4. Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders;The Journal of Allergy and Clinical Immunology: In Practice;2022-05

5. Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response;2021-09-01